Cancer vaccine study for unresectable stage III non-small cell lung cancer

This study is for people with stage 3 non-small cell lung cancer (NSCLC) that cannot be removed by surgery and has not spread to distant parts of the body. After completing standard chemotherapy and radiation treatment (chemoradiotherapy), participants are randomly assigned to receive either a cancer vaccine called Stimuvax or a placebo (dummy injection). Stimuvax works by activating the immune system to attack a protein found on many cancer cells. The study measures how long people live and how long it takes for the cancer to progress. You may be eligible if: - You are 18 years of age or older - You have confirmed stage III non-small cell lung cancer that cannot be surgically removed - You have completed at least 2 cycles of platinum-based chemotherapy and at least 50 Gy of radiation - Your cancer is stable or responding to treatment (confirmed within 4 weeks before joining) - You finished chemoradiotherapy between 4 and 12 weeks before joining the study - Your general health status (ECOG) is 0 or 1 You may NOT be eligible if: - You have had any other lung cancer-specific treatment besides chemoradiotherapy - You have metastatic (spread) disease or fluid around the lungs - You have an autoimmune disease or a known immune deficiency - You have significant heart, liver, or kidney disease - You are pregnant, breastfeeding, or not using effective contraception Talk to your doctor about whether this trial might be right for you.